THE TIMELESS UTILITY OF DUKE TREADMILL SCORE: A PROGNOSTIC TOOL FOR CORONARY ARTERY DISEASE SEVERITY ASSESSMENT

Authors

  • Lajpat Rai National Institute of Cardiovascular Diseases (NICVD), Hyderabad-Pakistan https://orcid.org/0000-0002-6060-2922
  • Mahesh Kumar Batra National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan https://orcid.org/0000-0001-6062-434X
  • Muhammad Naeem Mengal National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan
  • Rajesh Kumar National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan https://orcid.org/0000-0002-6580-7193
  • Jehangir Ali Shah National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan
  • Aziz Ur Rehman Memon National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan https://orcid.org/0009-0009-7526-0417
  • Syed Mohammad Haleem National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan https://orcid.org/0000-0002-7626-6062
  • Jawaid Akbar Sial National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan https://orcid.org/0000-0003-3700-127X
  • Tahir Saghir National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan
  • Musa Karim National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan https://orcid.org/0000-0001-7941-8191

DOI:

https://doi.org/10.55519/JAMC-01-12187

Keywords:

myocardial ischemia, Duke Treadmill Score, Syntax Score

Abstract

Background: This cross-sectional study aimed to evaluate the correlation between Duke Treadmill Score (DTS) and SYNTAX score and assess the role of DTS in predicting the severity of coronary artery disease (CAD) in patients with stable ischemic heart diseases. Methods: Conducted at a tertiary care cardiac center, the study included patients presenting to the outpatient department for the first time with angina and a positive exercise tolerance test (ETT), who underwent coronary angiogram. Correlation analysis was performed between DTS and SYNTAX score, and receiver operating characteristic (ROC) curve analysis was conducted for DTS to detect the presence (SYNTAX score ≥0) and severity (SYNTAX score ≥33) of CAD. Results: Out of 303 patients, 72.6% (220) were male, with a mean age of 53.31±10.11 years. CAD was confirmed in 79.9% (242) of patients. The mean SYNTAX score was 18.77±14.18, with 46.5% (141) categorized as low-risk, 27.1% as intermediate-risk, and 26.4% as high-risk. The mean DTS score was -6.09±4.5, with 13.9% categorized as high risk and the remaining 86.1% as intermediate or low risk. The Pearson correlation coefficient between DTS and SYNTAX score was -0.806 (p<0.001). The area under the curve (AUC) for DTS score in detecting the presence and severity of CAD was 0.992 [0.985–0.998] and 0.895 [0.860–0.929], respectively. Conclusion: A strong negative correlation was observed between SYNTAX score and DTS, highlighting the predictive value of DTS for assessing CAD severity. The DTS score demonstrated very high diagnostic accuracy in detecting the presence and severity of CAD.

Author Biography

Mahesh Kumar Batra, National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan

Correspondence:

National Institute of Cardiovascular Diseases (NICVD), Rafiqui (H.J.) Shaheed Road, Karachi-Pakistan.

Cell: +92 333 733 2262

Email: mahesh_bcmc@yahoo.com

References

1. Tilahun M, Gobena T, Dereje D, Welde M, Yideg G. Prevalence of Diabetic Retinopathy and Its Associated Factors among Diabetic Patients at Debre Markos Referral Hospital, Northwest Ethiopia, 2019: Hospital-Based Cross-Sectional Study. Diabetes Metab Syndr Obes 2020;13:2179–87.

2. Sabanayagam C, Banu R, Chee ML, Lee R, Wang YX, Tan G, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet 2018;7(2):140–9.

3. Chaudhary GM. Retinopathy in diabetic patients. Pak J Med Res 2005;44:82–87.

4. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health 2017;5(12):1221–34.

5. Kanski JJ. Clinical ophthalmology: a systematic approach. 6th Ed. Philadelphia: Elsevier Limited, 2007; p.582.

6. Shu D, Ting W, Ophth M, Chui G, Cheung M. Review diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol 2016;44(4):260–77.

7. Karimov M, Akhundova L. Anti-Vascular Endothelial Growth Factor Therapy as an Adjunct to Diabetic Vitrectomy. Open Ophthalmol J 2021;15(1):137–43.

8. Dervenis P, Dervenis N, Steel D, Sandinha T, Tranos P, Vasilakis P, et al. Intravitreal bevacizumab prior to vitrectomy for proliferative diabetic retinopathy: a systematic review, Ther Adv Ophthalmol 2021;13:25158414211059256.

9. Iyer SSR, Regan KA, Burnham JM, Chen CJ. Surgical Management of Diabetic Tractional Retinal Detachments. Surv Ophthalmol 2019;64(6):780–809.

10. Faisal SM, Tahir MA, Cheema AM, Anjum MI. Pars plana vitrectomy in vitreous hemorrhage with or without Intravitreal Bevacizumab a comparative overview. Pak J Med Sci. 2018;34(1):221–5.

11. Feng J, Li B, Wen J, Jiang Y. Preoperative timing of intravitreal bevacizumab injection for proliferative diabetic retinopathy patients. Ophthalmic Res 2018;60(4):250–7.

12. Mota SE, Nuñez-Solorio SM. Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol 2010;20(6):1047–52.

13. Pérez-Argandoña E, Verdaguer J, Zacharías S, González R. Preoperative intravitreal bevacizumab for proliferative diabetic retinopathy patients undergoing vitrectomy-First update. Medwave 2019;19(1):e7512.

14. Tsubota K, Usui Y, Wakabayashi Y, Suzuki J, Ueda S, Goto H. Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy. Clin Ophthalmol 2019;13:1063–1070.

15. Smith JM, Steel DH. Anti‐vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2015;2015(8):CD008214.

16. Al-Kharashi A, Galbinur T, Mandelcorn ED, Muni RH, Nabavi M, Kertes PJ. The adjunctive use of pre-operative intravitreal bevacizumab in the setting of proliferative diabetic retinopathy. Saudi J Ophthalmol 2016;30(4):217–20.

17. Demir M, Oba E, Can E, Kara O, Cinar S. Effect of bevacizumab injection before vitrectomy on intravitreal hemorrhage in pseudo phakic patients with proliferative diabetic retinopathy. Ophthalmol Eye Dis 2013;5:11–5.

18. Liang X, Zhang Y, Wang JX, Wang LF, Huang WR, Tang X. Intravitreal ranibizumab injection at the end of vitrectomy for diabetic vitreous hemorrhage (Observational Study). Medicine (Baltimore) 2019;98(20):e15735.

19. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nisar MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113(10):1695–705.

20. Zhao Y, Singh RP. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs Context 2018;7:212532.

21. Nagpal M, Choudhry N, Mehrotra N, Nagpal K, Lingam G. Efficacy of Preoperative Bevacizumab Injection for Vitrectomy in Diabetic Tractional Retinal Detachment. Word J Retina Vitreous 2011;1(2):52–5.

Published

2025-04-15

How to Cite

1.
Rai L, Batra MK, Mengal MN, Kumar R, Shah JA, Memon AUR, et al. THE TIMELESS UTILITY OF DUKE TREADMILL SCORE: A PROGNOSTIC TOOL FOR CORONARY ARTERY DISEASE SEVERITY ASSESSMENT. J Ayub Med Coll Abbottabad [Internet]. 2025 Apr. 15 [cited 2025 Jul. 19];37(1). Available from: https://www.jamc.ayubmed.edu.pk/index.php/jamc/article/view/12187

Issue

Vol. 37 No. 1 (2025): JOURNAL OF AYUB MEDICAL COLLEGE ABBOTTABAD

Section

ORIGINAL ARTICLE

License

Copyright (c) 2025 Lajpat Rai, Mahesh Kumar Batra, Muhammad Naeem Mengal, Rajesh Kumar, Jehangir Ali Shah, Aziz Ur Rehman Memon, Syed Mohammad Haleem, Jawaid Akbar Sial, Tahir Saghir, Musa Karim

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License  CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.

USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.